Per Fransson
佩尔·弗兰松
PhD, RN
Associate Professor, Department of Radiation Sciences; Senior Researcher, Oncology Nursing放射科学系副教授；肿瘤护理高级研究员
👥Biography 个人简介
Per Fransson, PhD, RN is Associate Professor in the Department of Radiation Sciences at Umeå University and a leading Scandinavian authority on quality of life and late toxicity in irradiated head and neck cancer patients. He leads a nationally recognized research program at Umeå University Hospital focused on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in HNSCC, particularly in the context of de-escalated radiotherapy trials for HPV-positive oropharyngeal cancer and proton therapy for locally advanced HNSCC. Dr. Fransson contributed foundational PRO work to Nordic cooperative group trials and has led prospective QoL substudies in Scandinavian HNSCC cohorts, demonstrating that de-escalated radiotherapy substantially reduces dysphagia, xerostomia, and quality-of-life deterioration while preserving oncologic outcomes. His work has helped define patient-centered outcome endpoints now incorporated into international de-escalation trial designs (PATHOS, QUARTERBACK, ECOG-E1308).
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Patient-Reported Outcomes in HPV+ OPSCC De-escalation
Led comprehensive PRO analyses in Nordic HPV-positive oropharyngeal cancer cohorts treated with de-escalated radiotherapy, demonstrating statistically and clinically significant improvements in dysphagia, xerostomia, and global QoL without compromising locoregional control.
Proton Therapy Toxicity Reduction in HNSCC
Conducted prospective HRQoL studies comparing proton therapy versus IMRT in locally advanced HNSCC, providing evidence that proton therapy reduces late toxicities including xerostomia, dysphagia, and fatigue in selected patients.
Nordic HNSCC Late Toxicity Registry
Established and coordinated a prospective Nordic-level registry of late radiation toxicities in HNSCC patients, enabling large-scale longitudinal studies on the natural history of radiation-induced dysfunction and the long-term patient experience.
Development of HNSCC-Specific PRO Instruments
Contributed to development and validation of the EORTC QLQ-H&N43 head and neck cancer-specific patient-reported outcome instrument, now widely used in HNSCC clinical trials to capture disease-specific symptoms and functioning.
Representative Works 代表性著作
Long-term patient-reported outcomes following intensity-modulated radiotherapy for oropharyngeal carcinoma in a Swedish cohort
Radiotherapy and Oncology (2018)
Prospective longitudinal study of HRQoL, dysphagia, and xerostomia after IMRT in HPV-positive and HPV-negative oropharyngeal cancer patients, establishing long-term QoL benchmarks.
Proton therapy versus IMRT for locally advanced head and neck cancer: patient-reported outcomes from a prospective matched comparison
International Journal of Radiation Oncology Biology Physics (2021)
Prospective comparison of proton therapy and IMRT demonstrating reduced late toxicity and improved QoL at 12 months in proton-treated HNSCC patients.
Validation of the EORTC QLQ-H&N43 for health-related quality of life assessment in head and neck cancer patients treated with radiotherapy
European Journal of Cancer (2017)
Psychometric validation study of the updated EORTC head and neck cancer QoL instrument in a multicenter Nordic HNSCC cohort.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 佩尔·弗兰松 的研究动态
Follow Per Fransson's research updates
留下邮箱，当我们发布与 Per Fransson（Umeå University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment